Viemed Healthcare, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VMD research report →
Range $14 – $14
Price Chart
About the company
Viemed Healthcare, Inc. , through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD.
- CEO
- Casey Hoyt
- IPO
- 2019
- Employees
- 1,490
- HQ
- Lafayette, LA, US
Get TickerSpark's AI analysis on VMD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $322.85M
- P/E
- 20.92
- Fwd P/E
- 21.30
- PEG
- 1.22
- P/S
- 1.04
- P/B
- 2.16
- EV/EBITDA
- 6.75
- Div Yield
- 0.00%
- Gross Margin
- 57.16%
- Op Margin
- 8.19%
- Net Margin
- 5.03%
- ROE
- 10.78%
- ROIC
- 11.09%
Latest fiscal year · YoY change
- Revenue
- $270.28M+20.5%
- Gross Profit
- $155.46M+16.7%
- Op Income
- $20.71M
- Net Income
- $14.93M+32.6%
- EPS
- $0.38+31.0%
- OCF Growth
- +32.8%
- FCF Growth
- +805.2%
- 52W High
- $12.61
- 52W Low
- $6.60
- 50D MA
- $9.28
- 200D MA
- $9.68
- Beta
- 1.03
- RSI (14)
- 34
- Avg Volume
- 247.43K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Viemed delivered record Q3 revenue and stronger earnings, then raised the low end of full-year revenue guidance while highlighting growth in sleep, maternal health, and ventilation.· November 5, 2026
- Record quarterly revenue of $80.7 million, up 12.2% year over year, with net income up 32% YoY.
- Adjusted EBITDA rose to $17.1 million with margin expansion to 21.1% from 17.6% in Q2.
- Management raised full-year revenue guidance to $316 million-$320 million and narrowed adjusted EBITDA guidance to $64 million-$66 million.
- Sleep therapy, resupply, and maternal health all contributed to growth; the company plans to add 2 new maternal health states per quarter starting in Q4.
- Cash flow was affected by AR timing, audits, and prepaid expenses, but management expects collections to normalize in Q4.
Viemed reported record Q3 revenue of $80.7 million, up 12.2% year over year and 3.3% sequentially. Net income attributable to Viemed was $4.6 million, or $0.11 per diluted share, versus $3.5 million, or $0.09 per diluted share, a year ago and $2.8 million, or $0.07 per diluted share, in Q2. Adjusted EBITDA was $17.1 million, up about 6% year over year and 24% sequentially, with adjusted EBITDA margin of 21.1% versus 22.4% a year ago and 17.6% in Q2. Gross profit was $46.2 million, or 57.3% of revenue, compared with 57.5% a year ago and 57.7% in Q2. For full-year 2026, management raised revenue guidance to $316 million-$320 million from $314 million-$320 million, narrowed adjusted EBITDA guidance to $64 million-$66 million from $64 million-$68 million, and lowered net CapEx guidance to 8%-9% of revenue from 8.5%-10%.
CEO Casey Hoyt framed the quarter as evidence that Viemed can grow under the new CMS coverage framework while converting more revenue into earnings. He emphasized strength in sleep therapy, early traction in maternal health, and a plan to expand maternal health into 2 additional states per quarter starting in Q4. He also said the company’s broad patient opportunities, compliance focus, and expanding referral relationships create years of runway across existing and new markets.
CFO William Todd Zehnder highlighted $4.6 million of net income, $17.1 million of adjusted EBITDA, and 21.1% adjusted EBITDA margin, noting that revenue growth outpaced SG&A and that SG&A fell $1.6 million sequentially to $35.5 million. Gross profit was $46.2 million, or 57.3% of revenue, and he said mix shifted toward lower-margin but less capital-intensive sales and services, with about 50 basis points of gross margin improvement expected once new supplier cost savings are fully implemented. He also said operating cash flow was $11.5 million, free cash flow was $4 million, cash was $9.7 million, borrowings were $5.3 million, and the company repaid $2.1 million of term debt plus repurchased 115 thousand shares for about $1 million; an additional $2 million term loan repayment was made in October. He attributed elevated AR and softer cash conversion to audit-related payment timing, system migration delays, and prepaid expenses, and said October collections were very strong.
Analysts focused on why sleep resupply and equipment/supply sales were not moving in lockstep, and management said Q2 was unusually strong while Q4 should be the biggest growth quarter for resupply due to seasonality and pull-through from higher PAP setups. On ventilator patients, management said the new CMS/NCD process has created some hesitation among referral sources and point-in-time patient counts were noisy, but they expect Q4 patient counts to improve and believe market share can be gained as education progresses. Analysts also pressed on maternal health rollout timing; management said the plan is a 2-state cadence, with new markets not fully developed in a quarter, and that growth builds over time as contracts, reimbursement, digital marketing, and field sales ramp. On M&A, management said the pipeline is active but they remain selective, preferring acquisitions only when they add geography, payer access, or a new service line.
The call showed Viemed can still post double-digit revenue growth and expand profitability at the same time, even with CMS rule changes and industry audit pressure. Management was upbeat about sleep resupply seasonality, maternal health expansion, and the ability to grow ventilation revenue under the new framework, while also signaling stronger cash flow and continued debt paydown.
Management acknowledged that compliance changes, audits, and system-related billing delays can slow patient onboarding, create AR pressure, and temporarily suppress cash conversion. Gross margin may also be pressured by a shift toward lower-margin sales and services, and the company said ventilator patient counts were a bit wobbly as referral sources adjust to the new rules.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 86.1%
- Shares Outstanding
- 37.89M
- Float Shares
- 32.61M
of shares held by institutions
168 13F filers
Buy/sell ratio 1.30. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 4.94M | ▲ 154.33K |
| Vanguard Group Inc | 1.78M | ▼ 21.98K |
| Forager Capital Management, LLC | 1.77M | ▼ 368.01K |
| Vanguard Capital Management LLC | 1.32M | ▼ 280 |
| Ameriprise Financial Inc | 1.30M | ▲ 294.70K |
| Geode Capital Management, LLC | 1.17M | ▲ 198.08K |
| Arrowstreet Capital, Limited Partnership | 1.04M | ▲ 257.39K |
| State Street Corp | 757.22K | ▼ 4.87K |
| Nantahala Capital Management, LLC | 714.67K | ▲ 82.23K |
| Martin & Co Inc | 701.68K | ▲ 360.91K |
| Panagora Asset Management Inc | 597.50K | ▲ 58.87K |
| Punch & Associates Investment Management, Inc. | 583.16K | ▲ 49.70K |
Held by 80 ETFs
Biggest fund positions in VMD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 19, 26 | Kaushal Nitin | other | 18,786 |
| Aug 17, 26 | Kaushal Nitin | other | 15,217 |
| Aug 19, 26 | Kaushal Nitin | other | 18,786 |
| Aug 19, 26 | Heltz Sabrina | other | 3,757 |
| Aug 19, 26 | Heltz Sabrina | other | 15,029 |
| Aug 19, 26 | Heltz Sabrina | sell | 3,757 |
| Aug 17, 26 | Heltz Sabrina | other | 12,174 |
| Aug 17, 26 | Heltz Sabrina | other | 3,043 |
| Aug 19, 26 | Heltz Sabrina | other | 3,757 |
| Aug 19, 26 | Heltz Sabrina | other | 15,029 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VMD coverage
Recent articles, reports, and earnings notes.
No research on VMD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VMD report →Viemed Healthcare, Inc. (VMD) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 8
Viemed Healthcare Q3 Earnings Call Highlights
marketbeat.com · Nov 6
Viemed Healthcare, Inc. (VMD) Lags Q3 Earnings and Revenue Estimates
zacks.com · Nov 4
Viemed Healthcare (VMD) Expected to Release Quarterly Earnings on Wednesday
defenseworld.net · Nov 2
Viemed Healthcare Maps Growth in Home Respiratory Care, Sleep and Maternal Health
marketbeat.com · Oct 22
Viemed Healthcare Announces Third Quarter 2026 Earnings Conference Call Details
accessnewswire.com · Oct 22
Do Options Traders Know Something About Viemed Stock We Don't?
zacks.com · Oct 7
Viemed Healthcare, Inc. to Present at the 20th Annual LD Micro Main Event
newsfilecorp.com · Oct 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.